Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Whole-Body Irradiation 6Busulfan 5Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Azacitidine 4venetoclax 3fludarabine 3Tacrolimus 3Cyclosporine 3Biopsy 3Vorinostat 2Specimen Handling 2Rituximab 2Methotrexate 2Etoposide 2Cytarabine 2Antilymphocyte Serum 2thymoglobulin 1pegylated granulocyte colony-stimulating factor 1merphos 1ivosidenib 1decitabine and cedazuridine drug combination 1cedazuridine 1Thiotepa 1TAK-243 1Stem Cell Transplantation 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × TAK-243 × 90 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡